- Home
- MGNX vs LGO Comparison
MGNX vs LGO Comparison
Compare MGNX & LGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- LGO
- Stock Information
- Founded
- MGNX 2000
- LGO 1988
- Country
- MGNX United States
- LGO Canada
- Employees
- MGNX N/A
- LGO N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- LGO
- Sector
- MGNX Health Care
- LGO
- Exchange
- MGNX Nasdaq
- LGO Nasdaq
- Market Cap
- MGNX 99.7M
- LGO 86.9M
- IPO Year
- MGNX 2013
- LGO 2007
- Fundamental
- Price
- MGNX $1.76
- LGO $1.52
- Analyst Decision
- MGNX Hold
- LGO Strong Buy
- Analyst Count
- MGNX 5
- LGO 1
- Target Price
- MGNX $3.25
- LGO $3.70
- AVG Volume (30 Days)
- MGNX 582.9K
- LGO 139.7K
- Earning Date
- MGNX 08-14-2025
- LGO 08-12-2025
- Dividend Yield
- MGNX N/A
- LGO N/A
- EPS Growth
- MGNX N/A
- LGO N/A
- EPS
- MGNX N/A
- LGO N/A
- Revenue
- MGNX $165,495,000.00
- LGO $108,526,000.00
- Revenue This Year
- MGNX N/A
- LGO N/A
- Revenue Next Year
- MGNX N/A
- LGO $54.96
- P/E Ratio
- MGNX N/A
- LGO N/A
- Revenue Growth
- MGNX 303.47
- LGO N/A
- 52 Week Low
- MGNX $0.99
- LGO $1.12
- 52 Week High
- MGNX $5.10
- LGO $2.84
- Technical
- Relative Strength Index (RSI)
- MGNX 57.55
- LGO 60.34
- Support Level
- MGNX $1.69
- LGO $1.32
- Resistance Level
- MGNX $1.87
- LGO $1.56
- Average True Range (ATR)
- MGNX 0.12
- LGO 0.08
- MACD
- MGNX 0.02
- LGO 0.02
- Stochastic Oscillator
- MGNX 71.59
- LGO 92.86
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About LGO Largo Inc.
Largo Inc is committed to the production and supply of high-quality vanadium products. The company is also focused on the advancement of renewable energy storage solutions through Largo Clean Energy and its vanadium redox flow battery technology. The Company is engaged in the mining, exploration, and development of mineral properties, predominantly in Brazil, through which it produces and supplies vanadium products VPURE Flake, VPURE+ Flake, and VPURE+ Powder. The company has operating segments: sales & trading, mine properties, which generates key revenue, corporate, exploration and evaluation properties, Clean Energy, and Largo Physical Vanadium.